Back to News

Explore the Latest #NephTrials Discussion on Dapagliflozin and CKD on the ISN’s Twitter Feed

The latest #NephTrials online discussion took place on March 10.

Access the Twitter thread here.

Twitter attendees joined Ron Gansevoort, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath to discuss the RENAL LIFECYCLE trial.

The conversation examined the composite and secondary outcomes of a randomized control trial investigating the effects of dapagliflozin on people with severe chronic kidney disease (CKD).

Help us advance kidney health worldwide
Join the ISN Subscribe to ISN Newsletter
Back to News